() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: 48 North Cannabis

48North Cannabis Corp. Signs Supply Agreement with Good & Green

Oct. 1, 2018 /CNW/ - 48North Cannabis Corp. ("48North" or the "Company") (TSXV:NRTH) today announced that it has entered a supply agreement (the "Agreement") with 2599708 Ontario Inc. ("Good & Green"), a socially responsible, organic cannabis company and late-stage ACMPR applicant. Under the terms of the Agreement, signed September 28, 2018, 48North will pay Good & Green $1,500,000 in exchange for 6,000 kilograms of organically sun-grown, dried cannabis, as permitted under the Cannabis Act, for use in extraction, to be delivered on or before December 31, 2019.
Read more

48North Cannabis Corp. Licenses Colorado’s Mother & Clone’s Proprietary Cannabis Rapid-Absorption Sublingual Nanospray

Sept. 25, 2018 /CNW/ - 48North Cannabis Corp. ("48North" or the "Company") (TSXV:NRTH), a leading licensed cannabis producer focused on the women's health and wellness market, today announced a licensing agreement with Mother & Clone, Inc. ("Mother & Clone"), a Colorado-based company producing proprietary cannabis sublingual nanosprays (a form of measured microdosing). This agreement follows the Company's announcement that it received a supplemental license from Health Canada for the extraction and production of cannabis oil. Canadian production and sale of Mother & Clone products are expected to commence after the Company receives its Health Canada license amendment permitting the sale of cannabis oil.
Read more

Rooted in the Netherlands and Grown in Northern Ontario, 48North Cannabis Corp. Announces its Top Six New Cultivars

Sept. 20, 2018 /CNW/ - 48North Cannabis Corp. ("48North" or the "Company") (TSXV:NRTH) is announcing the completion of Phase I of its project to bring its top performing cannabis cultivars to the Canadian market. Following the importation of 6,650 cannabis seeds from Netherlands-based MariPharm B.V., the Company embarked on a project to select and cultivate its most promising phenotypes at the Company's wholly-owned licensed facility, DelShen Therapeutics Corp. ("DelShen") located in Kirkland Lake, Ontario.
Read more